posted on 2023-06-13, 14:37authored byHuiqun Hu, Shi Yuan Hua, Xiuhui Lin, Feng Lu, Wenting Zhang, Lihui Zhou, Jiarong Cui, Ruoxi Wang, Jingyan Xia, Feng Xu, Xiaoyuan Chen, Min Zhou
Acute
methicillin resistant Staphylococcus aureus (MRSA)
pneumonia is one of the most frequently seen lung infection
diseases with high morbidity and mortality. It is urgent to explore
an efficient antibacterial strategy owing to the increase of drug
resistance, virulence, and pathogenicity of MRSA. It was found that
Fe3O4 can induce ferroptosis in MRSA, but its
effect was inhibited by glutathione (GSH) to a certain extent, while
cinnamaldehyde (CA) can enhance ferroptosis by consuming GSH. As a
bacterial quorum sensing (QS) inhibitor, CA can suppress the QS system
and further exert its antibacterial and antibiofilm effects. Here,
we developed an Fe3O4-based ferroptosis inducer
to promote ferroptosis in MRSA, interrupt the QS, destroy biofilm,
and thus effectively treat acute MRSA pneumonia. We used sodium alginate
(SA) to wrap Fe3O4 and CA to form particles,
and then coated the surface with a hybrid biomimetic membrane composed
of an erythrocyte membrane and platelet membrane to obtain lung targeted
antibacterial particles (mFe-CA). Under ultrasonic (US) stimulation,
mFe-CA can efficiently release Fe3O4 and CA,
thereby synergically inducing MRSA death with the characteristics
of ferroptosis, including mass ROS production, lipid peroxidation,
GSH depletion, and respiratory chain suppression. Furthermore, mFe-CA
+ US can inhibit the QS system, remove biofilms, and reduce strain
virulence. In the mouse model of MRSA pneumonia, mFe-CA + US treatment
markedly advanced the survival rate of the mice, reduced the bacterial
load in the lungs, and alleviated the inflammatory damage, but there
was no obvious toxicity. This study proposes an antibacterial substitute
to induce ferroptosis of MRSA, which may provide a foreground for
overcoming microbial drug resistance and fighting biofilm-associated
infections and also provides a target and theoretical basis for clinical
treatment of acute MRSA pneumonia.